Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 5 of 8 for:    savara

Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (IMPALA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02702180
Recruitment Status : Completed
First Posted : March 8, 2016
Last Update Posted : December 24, 2019
Information provided by (Responsible Party):
Savara Inc.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : April 19, 2019
Actual Study Completion Date : September 27, 2019